Normal pressure hydrocephalus.

PubWeight™: 1.25‹?› | Rank: Top 10%

🔗 View Article (PMID 17226742)

Published in Semin Neurol on February 01, 2007

Authors

Diamanto Tsakanikas1, Norman Relkin

Author Affiliations

1: Department of Neurology and Neuroscience, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York 10021, USA.

Articles by these authors

Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med (2004) 2.82

Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol (2007) 2.30

Low-dose acetazolamide reverses periventricular white matter hyperintensities in iNPH. Neurology (2014) 2.08

Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord (2003) 1.79

Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol (2002) 1.68

The value of supplemental prognostic tests for the preoperative assessment of idiopathic normal-pressure hydrocephalus. Neurosurgery (2005) 1.52

Natural human antibodies to amyloid beta peptide. Autoimmun Rev (2008) 1.20

Surgical management of idiopathic normal-pressure hydrocephalus. Neurosurgery (2005) 1.15

Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int (2003) 1.13

Outcome of shunting in idiopathic normal-pressure hydrocephalus and the value of outcome assessment in shunted patients. Neurosurgery (2005) 1.12

Increased diffusion in the brain of professional boxers: a preclinical sign of traumatic brain injury? AJNR Am J Neuroradiol (2003) 1.01

Development of guidelines for idiopathic normal-pressure hydrocephalus: introduction. Neurosurgery (2005) 0.99

Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin Chem (2006) 0.97

Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol (2010) 0.97

Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis (2002) 0.91

The Network Modification (NeMo) Tool: elucidating the effect of white matter integrity changes on cortical and subcortical structural connectivity. Brain Connect (2013) 0.89

Human cerebrospinal fluid apolipoprotein E isoforms are apparently inefficient at complexing with synthetic Alzheimer's amyloid-[beta] peptide (A[beta] 1-40 ) in vitro. Mol Med (2002) 0.83

Exploring the brain's structural connectome: A quantitative stroke lesion-dysfunction mapping study. Hum Brain Mapp (2015) 0.82

Disease-modifying approaches to Alzheimer's disease: challenges and opportunities-Lessons from donepezil therapy. Alzheimers Dement (2008) 0.81

Longitudinal effects of intravenous immunoglobulin on Alzheimer's cerebrospinal fluid proteome. Electrophoresis (2014) 0.75

Cholinergic components of frontal lobe function and dysfunction. Handb Clin Neurol (2008) 0.75

Pesticide exposure and dementia. J Am Geriatr Soc (2004) 0.75